Total Valuation
SAMSUNG BIOLOGICS Co., Ltd. has a market cap or net worth of ₩68.74T. The enterprise value is $69.12M.
Market Cap₩68.74T
Enterprise Value$69.12M
Share Statistics
SAMSUNG BIOLOGICS Co., Ltd. has 46,290,950 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding46,290,950
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
SAMSUNG BIOLOGICS Co., Ltd.’s return on equity (ROE) is 0.24 and return on invested capital (ROIC) is 17.81%.
Return on Equity (ROE)0.24
Return on Assets (ROA)0.16
Return on Invested Capital (ROIC)17.81%
Return on Capital Employed (ROCE)0.24
Revenue Per Employee835.38M
Profits Per Employee295.94M
Employee Count5,455
Asset Turnover0.41
Inventory Turnover0.97
Valuation Ratios
The current PE Ratio of SAMSUNG BIOLOGICS Co., Ltd. is 34.6. SAMSUNG BIOLOGICS Co., Ltd.’s PEG ratio is 0.68.
PE Ratio34.6
PS Ratio17.20
PB Ratio10.52
Price to Fair Value10.52
Price to FCF91.55
Price to Operating Cash Flow28.24
PEG Ratio0.68
Income Statement
In the last 12 months, SAMSUNG BIOLOGICS Co., Ltd. had revenue of 4.56T and earned 1.78T in profits. Earnings per share was 38.59K.
Revenue4.56T
Gross Profit2.48T
Operating Income2.07T
Pretax Income2.12T
Net Income1.78T
EBITDA2.78T
Earnings Per Share (EPS)38.59K
Cash Flow
In the last 12 months, operating cash flow was 2.33T and capital expenditures -873.43B, giving a free cash flow of 1.46T billion.
Operating Cash Flow2.33T
Free Cash Flow1.46T
Free Cash Flow per Share31.52K
Dividends & Yields
SAMSUNG BIOLOGICS Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.23
52-Week Price Change-8.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
SAMSUNG BIOLOGICS Co., Ltd. upcoming earnings date is Oct 27, 2026, Before Open (Confirmed).
Last Earnings DateJul 23, 2026
Next Earnings DateOct 27, 2026
Ex-Dividend Date―
Financial Position
SAMSUNG BIOLOGICS Co., Ltd. as a current ratio of 1.74, with Debt / Equity ratio of 15.08%
Current Ratio1.74
Quick Ratio0.90
Debt to Market Cap0.01
Net Debt to EBITDA0.28
Interest Coverage Ratio70.93
Taxes
In the past 12 months, SAMSUNG BIOLOGICS Co., Ltd. has paid 504.30B in taxes.
Income Tax504.30B
Effective Tax Rate0.24
Enterprise Valuation
SAMSUNG BIOLOGICS Co., Ltd. EV to EBITDA ratio is 28.46, with an EV/FCF ratio of 92.46.
EV to Sales17.37
EV to EBITDA28.46
EV to Free Cash Flow92.46
EV to Operating Cash Flow35.21
Balance Sheet
SAMSUNG BIOLOGICS Co., Ltd. has ₩1.62T in cash and marketable securities with ₩1.19T in debt, giving a net cash position of ₩425.87B billion.
Cash & Marketable Securities₩1.62T
Total Debt₩1.19T
Net Cash₩425.87B
Net Cash Per Share₩9.20K
Tangible Book Value Per Share₩159.84K
Margins
Gross margin is 39.66%, with operating margin of 45.41%, and net profit margin of 39.16%.
Gross Margin39.66%
Operating Margin45.41%
Pretax Margin46.49%
Net Profit Margin39.16%
EBITDA Margin61.04%
EBIT Margin47.13%
Analyst Forecast
The average price target for SAMSUNG BIOLOGICS Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-9.64%
EPS Growth Forecast54.40%